Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation

PURPOSE: Trastuzumab emtansine (T-DM1) is the standard treatment in the current second-line therapy of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. However, a useful therapy after T-DM1 resistance has not been established. In this study, we established two diffe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita-Kashima, Yoriko, Shu, Sei, Osada, Masahiro, Fujimura, Takaaki, Yoshiura, Shigeki, Harada, Naoki, Yoshimura, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561595/
https://www.ncbi.nlm.nih.gov/pubmed/32997196
http://dx.doi.org/10.1007/s00280-020-04138-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7561595/
https://www.ncbi.nlm.nih.gov/pubmed/32997196
http://dx.doi.org/10.1007/s00280-020-04138-5

Ejemplares similares